Details

Autor(en) / Beteiligte

• GU, Chao
• GAO, Yuan
• HAN, Ruilan
• GUO, Min
• LIU, Hong
• GAO, Jie
• LIU, Yang
• LI, Bing
• SUN, Lijun
• BU, Ren
• HAO, Jian
• MENG, Yan
• AN, Ming
• CAO, Xiaodong
• SU, Changhai
• LI, Gang

Titel

Metabolomics of clinical samples reveal the treatment mechanism of lanthanum hydroxide on vascular calcification in chronic kidney disease

Ist Teil von

• Proceedings of the Japan Academy, Series B, 2022/07/29, Vol.98(7), pp.361-377

Ort / Verlag

Ueno Park: The Japan Academy

Erscheinungsjahr

2022

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Previous studies showed that lanthanum hydroxide (LH) has a therapeutic effect on chronic kidney disease (CKD) and vascular calcification, which suggests that it might have clinical value. However, the target and mechanism of action of LH are unclear. Metabolomics of clinical samples can be used to predict the mechanism of drug action. In this study, metabolomic profiles in patients with end-stage renal disease (ESRD) were used to screen related signaling pathways, and we verified the influence of LH on the ROS-PI3K-AKT-mTOR-HIF-1α signaling pathway by western blotting and quantitative real-time RT-qPCR in vivo and in vitro. We found that ROS and SLC16A10 genes were activated in patients with ESRD. The SLC16A10 gene is associated with six significant metabolites (L-cysteine, L-cystine, L-isoleucine, L-arginine, L-aspartic acid, and L-phenylalanine) and the PI3K-AKT signaling pathway. The results showed that LH inhibits the ESRD process and its cardiovascular complications by inhibiting the ROS-PI3K-AKT-mTOR-HIF-1α signaling pathway. Collectively, LH may be a candidate phosphorus binder for the treatment of vascular calcification in ESRD.